Posted by Michael Wonder on 01 Oct 2025
Disc Medicine announces submission of new drug application to US FDA for accelerated approval of bitopertin for patients with erythropoietic protoporphyria
30 September 2025 - Disc is seeking accelerated approval and priority review of its new drug application submission.
Disc Medicine today announced the submission of a new drug application to the US FDA for bitopertin for patients aged 12 years and older with erythropoietic protoporphyria, including X-linked protoporphyria.
